Case Report The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma Eko A. Pangarsa , 1 Ridho M. Naibaho , 2,3 Vina Yunarvika , 1 Budi Setiawan , 1 Damai Santosa , 1 and Catharina Suharti 1 1 Subdivion of Hematology and Medical Oncology, Medical Faculty of Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia 2 Trainee in Hematology and Medical Oncology, Medical Faculty of Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia 3 DepartmentofInternalMedicine,ParikesitHospital,MulawarmanSchoolofMedicine,Samarinda,EastKalimantan,Indonesia Correspondence should be addressed to Eko A. Pangarsa; ekopangarsa90@gmail.com Received 1 August 2021; Accepted 15 October 2021; Published 3 November 2021 Academic Editor: Kostas Konstantopoulos Copyright © 2021 Eko A. Pangarsa et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Up to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among which early relapse confers a poor outcome. With salvage chemotherapy followed by autologous stem cell transplantation (ASCT), the long- term remission rate is 30%. We report our experience of using a modified-BEAM conditioning regimen without BCNU consisting of etoposide, cytarabine, and melphalan (EAM) in a patient with relapsed Hodgkin’s lymphoma. Before transplantation, the patient achieved second complete remission (CR2) using brentuximab vedotin and ESHAP (BR- ESHAP) chemotherapy. e ASCT went well without significant complications. is case demonstrated the considerable efficacy of EAM protocol as a conditioning regimen in terms of sufficient ablative capabilities, and the patient showed a successful hematopoietic engraftment. Although durability of the disease-free survival needs further observation, it had nearly 18 months of complete remission and the patient was in good performance status at the time of writing this manuscript. 1.Background BEAM (carmustine (BCNU), etoposide, Ara-cytarabine, and melphalan) is considered as the standard condi- tioning regimen for autologous stem cell transplantation (ASCT) in malignant lymphoma [1, 2]. Unexpectedly, since 2010, the oncological community faced the issue of shortage of some essential chemotherapy drugs, among which was BCNU, one of the central components of the BEAM protocol. Physicians were, thus, forced to change their standard for those regimens in which a component was no longer available: two common solutions were to replace the missing drug with a substitutive agent or even to skip the unavailable drug, trusting that the modified regimen would yield a noninferior result in terms of efficacy and better toxicity profile [3]. BCNU shortage was also reported in Indonesia. So far, we have always been hindered to perform hematopoietic stem cell transplants by the unavailability of this particular drug in the national formularies [4]. We then employed a BEAM-like myeloablative protocol without the letter “B” consisting of etoposide, Ara-cytarabine, and melphalan (EAM) for a pre- parative ASCT regimen [5], of which one of the cases will be reported here in a patient with Hodgkin’s lymphoma. Hindawi Case Reports in Hematology Volume 2021, Article ID 9632427, 6 pages https://doi.org/10.1155/2021/9632427